Edwards Lifesciences Corporation $EW Shares Sold by MassMutual Private Wealth & Trust FSB

Key Points

• MassMutual Private Wealth & Trust FSB significantly reduced its holding in Edwards Lifesciences by 92.0%, ending the quarter with only 1,738 shares valued at approximately $136,000.
• Despite some institutional sell-offs, other investors like Jennison Associates LLC and UBS AM increased their stakes, showing a mixed sentiment among institutional holders.
• Edwards Lifesciences reported a quarterly earnings per share (EPS) of $0.67, beating estimates, with revenues of $1.53 billion, representing an 11.9% year-over-year increase.

MassMutual Private Wealth & Trust FSB cut its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 92.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,738 shares of the medical research company's stock after selling 19,921 shares during the quarter. MassMutual Private Wealth & Trust FSB's holdings in Edwards Lifesciences were worth $136,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of EW. Jennison Associates LLC grew its stake in Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after purchasing an additional 2,576,383 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Edwards Lifesciences by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company's stock worth $491,673,000 after purchasing an additional 264,311 shares in the last quarter. Nuveen LLC acquired a new position in Edwards Lifesciences during the 1st quarter worth $330,881,000. Invesco Ltd. grew its stake in Edwards Lifesciences by 2.6% during the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company's stock worth $310,773,000 after purchasing an additional 107,241 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Edwards Lifesciences by 5.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company's stock worth $287,140,000 after purchasing an additional 198,882 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 0.2%

Shares of NYSE EW opened at $74.39 on Friday. The business has a 50-day moving average price of $78.69 and a 200 day moving average price of $75.51. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock has a market cap of $43.67 billion, a PE ratio of 10.70, a price-to-earnings-growth ratio of 3.60 and a beta of 1.07. Edwards Lifesciences Corporation has a 52-week low of $64.00 and a 52-week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the business posted $0.70 EPS. The company's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Analyst Ratings Changes

EW has been the subject of several analyst reports. Mizuho boosted their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Evercore ISI boosted their target price on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a research note on Friday, July 25th. Finally, BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research report on Tuesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $87.17.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.